A carregar...
PCSK9 Inhibitors Show Value for Patients and the U.S. Healthcare System
OBJECTIVES: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were approved by the U.S. Food and Drug Administration (FDA) as cholesterol-lowering therapies for patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease. This study estimates the long-term he...
Na minha lista:
| Publicado no: | Value Health |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5929151/ https://ncbi.nlm.nih.gov/pubmed/29241886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2017.05.014 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|